Biogen Inc

2026. júl. 16. 19:02 UTC

Biogen partners with Synapticure to launch a virtual ataxia care program. Shares are higher today, reflecting positive sentiment since Wednesday's close.

2026. júl. 15. 23:36 UTC

Biogen Inc. shares declined in after-market trading, reflecting ongoing weakness amid broader market caution related to geopolitical tensions involving the U.S. and Iran.

2026. júl. 14. 23:41 UTC

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

2026. júl. 13. 23:06 UTC

Biogen received FDA approval for LEQEMBI IQLIK, a subcutaneous Alzheimer's treatment, boosting shares modestly higher in after-market trading.

2026. júl. 10. 21:01 UTC

Biogen Inc shares declined in after-market trading, reversing an initial uptick and nearing the lower end of their one-month trading range. No specific news was identified.

2026. júl. 9. 23:46 UTC

Biogen Inc shares are trading lower in after-market hours, continuing a trend of five consecutive daily declines without any specific news to explain the movement.

2026. júl. 8. 23:56 UTC

Biogen Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing lower, with no specific news identified for the decline.

2026. júl. 7. 23:31 UTC

Biogen Inc shares are higher in after-market trading following Tuesday's close, amid broader market volatility but stable performance above its 20-day moving average.

2026. júl. 6. 23:56 UTC

Biogen Inc. shares are higher in after-market trading, reflecting a slight upward movement since Monday's close and settling near the upper end of their one-month range.

2026. júl. 2. 22:16 UTC

Biogen Inc shares are lower in after-market hours, reflecting a decline since Thursday's close amid mixed market sentiment and a weaker jobs report.

2026. júl. 1. 20:07 UTC

Biogen Inc. shares are lower as broader market sell-offs raise volatility. Barclays notes vulnerabilities in U.S. equity markets affecting investor sentiment.

2026. jún. 30. 19:56 UTC

Biogen will present new Alzheimer’s data at the AAIC 2026, including findings from the Phase 2 CELIA study and LEQEMBI analyses. Shares are higher today.

2026. jún. 29. 23:02 UTC

Biogen will present new Alzheimer’s data at AAIC 2026, but shares are lower in after-market hours amid broader market volatility and geopolitical tensions.

2026. jún. 26. 19:51 UTC

Biogen Inc pauses investment in most legacy Apellis programs, aligning with current objectives. Shares are higher today, reflecting positive investor response to the restructuring.

2026. jún. 25. 22:36 UTC

Biogen Inc's shares are higher in after-market trading, reflecting a notable upward trajectory since Thursday's close amid mixed broader market results.

2026. jún. 24. 20:04 UTC

Biogen Inc shares are higher today, supported by a broader rally in the Biotechnology sector and increased interest noted on social media.

2026. jún. 23. 23:21 UTC

Biogen Inc shares are higher in after-market trading, reaching a session high. No specific news was identified to explain the unusual price movement.

2026. jún. 22. 23:46 UTC

Biogen Inc. shares traded lower in after-market hours following modest fluctuations since Monday's close, with the price dipping after a brief session high.

2026. jún. 18. 20:05 UTC

Biogen Inc. plans to acquire RayThera Inc. for up to $1 billion, but shares are declining amid broader Biotechnology sector weakness.

2026. jún. 17. 23:06 UTC

Biogen Inc announced a definitive agreement to acquire RayThera Inc. for up to $1 billion, enhancing its immunology pipeline. Shares are trading higher after the news.

2026. jún. 16. 19:46 UTC

Biogen Inc. shares are lower amid an investigation announcement linked to the Phase 2 CELIA study's failure and failed negotiations over Skyclarys.

2026. jún. 12. 19:51 UTC

Biogen Inc. shares are higher today, breaking a recent trend. Broader market sentiment is shaped by inflation concerns and optimism about upcoming IPOs.

2026. jún. 11. 19:51 UTC

Biogen Inc is advancing as the biotechnology sector gains. Earlier in the session, shares pulled back from a high but resumed their upward trajectory.

2026. jún. 10. 19:36 UTC

Biogen Inc. is under investigation by Bronstein, Gewirtz & Grossman, LLC, following disappointing Phase 2 CELIA study results. Shares are trading lower amid ongoing scrutiny.

2026. jún. 9. 23:16 UTC

Biogen Inc. shares declined in after-market trading, moving lower since Tuesday's close. The asset remains above its 20-day moving average.

2026. jún. 8. 20:06 UTC

Biogen Inc. shares are lower amid negative sentiment over its Phase 2 CELIA study results, despite a recent upgrade to a Buy rating.

2026. jún. 5. 19:16 UTC

Biogen shares are gaining following FDA's Breakthrough Therapy Designation for salanersen in spinal muscular atrophy, despite pulling back from earlier session highs.

2026. jún. 4. 22:06 UTC

Biogen Inc. received FDA Breakthrough Therapy Designation for salanersen, aimed at treating spinal muscular atrophy, with shares trading higher in after-market hours.

2026. jún. 3. 20:03 UTC

Biogen Inc. announced fourteen abstracts accepted for presentation at upcoming nephrology congresses, contributing to higher trading shares amid positive market sentiment.

2026. jún. 2. 20:06 UTC

Biogen Inc. shares declined during Tuesday's session, continuing a trend of lower closes, amid broader weakness in the biotechnology sector.